CytoAgents
- Company typePrivate
- Founded2018
- HeadquartersPittsburgh, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
CytoAgents firmographics
Firmographics- Name
- CytoAgents
- Legal name
- CytoAgents, Inc.
- Website
- https://cytoagents.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
CytoAgents industry classification
Industry- Product category
- Immunomodulatory Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
- akta.pro secondary industries
- CAR-T & TCR-T Therapies (HLAAABAC), Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)
Keywords
Where CytoAgents is headquartered
LocationHeadquarters
- HQ city
- Pittsburgh
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CytoAgents business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical-stage biotechnology company developing CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) and related inflammatory conditions. Revenue will be generated through pharmaceutical product sales upon successful clinical development and regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
CytoAgents product offering
Product offeringCore offering
CytoAgents develops CTO1681, a novel orally bioavailable steroid-sparing small molecule immunomodulator that selectively targets prostacyclin/prostaglandin receptors to block NF-kB and PGE2 inflammatory signaling pathways. The drug is being advanced through clinical trials for cytokine release syndrome (CRS) and ICANS in CAR T-cell therapy patients, with a pipeline-in-a-pill expansion strategy into pulmonary arterial hypertension, asthma, and atopic dermatitis.
Product overview
CytoAgents is advancing CTO1681 (formerly known as GP1681), a novel, orally bioavailable small molecule drug that acts as a steroid-sparing inhibitor of prostaglandin/prostacyclin-mediated inflammation. The company operates a 'pipeline-in-a-pill' strategy, where CTO1681 targets multiple indications including CAR T-cell and TCE therapy-related CRS and ICANS, pulmonary arterial hypertension, asthma, and atopic dermatitis. CTO1681 modulates inflammatory signaling through selective IP, EP4, EP3, and EP1 receptors while sparing EP2 receptor activity, providing a differentiated approach compared to JAK inhibitors.
Differentiator
Problem solved
Functional benefit
Products and services
- CTO1681 CTO1681 is a novel, orally bioavailable steroid-sparing small molecule immunomodulator that selectively targets prostacyclin/prostaglandin receptors (IP, EP4, EP3, EP1 while sparing EP2) to modulate cytokine signaling without impairing normal immune function. It is being developed for prevention and treatment of cytokine release syndrome (CRS) and ICANS in CAR T-cell and bispecific T-cell engager therapy patients, with pipeline expansion into pulmonary arterial hypertension, asthma, and atopic dermatitis.
Quantifiable outcome
- CTO1681 was well tolerated at 10μg TID with no serious adverse events reported in Phase 1b/2a clinical trial; trial is now enrolling a higher dose cohort
- +2 more outcomes
Companies that use CytoAgents
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
CytoAgents technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CytoAgents partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- UPMC Hillman Cancer CentercoreFirst patient enrolled in Phase 1b/2a clinical trial for CRS in CAR T-cell therapy at UPMC Hillman Cancer Center, the largest network of outpatient cancer centers in the tri-state area of Pennsylvania, Ohio, and West Virginia.
- NovotechminorContract research organization (CRO) partnership for Phase 1 clinical trial of GP1681 for COVID-19 cytokine storm treatment in Australia.
- CMAX Clinical ResearchminorClinical trial unit partnership for Phase 1 trial of GP1681 for COVID-19 cytokine storm treatment, conducted in Australia as a randomized, double-blind, placebo-controlled study.
- Quotient SciencescoreCollaboration to accelerate development of lead COVID-19 drug candidate GP1681 into human clinical trials. Quotient provided formulation, manufacturing expertise, and rapid drug product supply for Phase I and II testing.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
CytoAgents competitors and assessment
Company assessmentDirect peers
- Kiniksa Pharmaceuticals: Clinical-stage immunology company developing therapies for inflammatory and autoimmune diseases, including programs addressing CAR T-cell related toxicities. Directly comparable as a small-cap biotech focused on cytokine-driven and inflammatory conditions with multiple pipeline assets.
- Incyte Corporation: Markets Jakafi (ruxolitinib) which is used off-label for steroid-refractory CRS, and is a direct competitor in the inflammation and immunology space. CytoAgents' newly appointed CSO Michael Howell previously contributed to Jakafi's development at Incyte.
- United Therapeutics: Market leader in pulmonary arterial hypertension (PAH) with approved prostacyclin analogues (Tyvaso, Remodulin). CytoAgents' CTO1681 also targets the IP/prostacyclin pathway for PAH, making United Therapeutics a key reference competitor for that indication.
Broad incumbents
- Roche (Genentech): Owns Actemra (tocilizumab), the only FDA-approved therapy for CAR T-cell-induced cytokine release syndrome. Directly competes in the CRS indication but as part of a much broader immunology and oncology portfolio.
- Regeneron / Sanofi (Dupixent): Dupixent (dupilumab) is the market-leading biologic for atopic dermatitis and asthma. CytoAgents' CTO1681 targets both indications, making this franchise a key indirect competitor and benchmark for the inflammation pipeline.
- AbbVie (Rinvoq): Rinvoq (upadacitinib) is a leading JAK inhibitor for atopic dermatitis and other inflammatory conditions. CTO1681 explicitly positions itself as a non-JAK alternative, making AbbVie a critical competitive reference point.
- Acceleron Pharma (Merck): Developed sotatercept (Winrevair) for PAH, representing a new mechanism in the indication. Acquired by Merck in 2021, it exemplifies the type of large-pharma exit opportunity for successful PAH-focused biotechs like CytoAgents.
Emerging players
- Cartesian Therapeutics: Clinical-stage company developing cell therapies and treatments for autoimmune and inflammatory conditions, including programs relevant to CAR T-cell therapy toxicities. Comparable as a smaller emerging player targeting cytokine-driven complications.
- AnaptysBio: Clinical-stage biotechnology company developing inflammation and immunology therapeutics. Comparable in size and stage to CytoAgents with a pipeline of antibody-based inflammatory disease candidates.
- Aldeyra Therapeutics: Small clinical-stage biotech developing novel small-molecule therapies for immune-mediated diseases. Comparable in size, stage, and therapeutic focus on inflammation-driven conditions.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
CytoAgents social profiles
Digital presenceCytoAgents financial estimates
Financial estimateRevenue estimate
Valuation estimate
CytoAgents leadership team
Management profileNumber of profiles
Profiles5 records
CytoAgents funding detail
Funding detailFunding overview
Funding rounds13 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CytoAgents M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CytoAgents
What does CytoAgents do?
CytoAgents develops CTO1681, a novel orally bioavailable steroid-sparing small molecule immunomodulator that selectively targets prostacyclin/prostaglandin receptors to block NF-kB and PGE2 inflammatory signaling pathways. The drug is being advanced through clinical trials for cytokine release syndrome (CRS) and ICANS in CAR T-cell therapy patients, with a pipeline-in-a-pill expansion strategy into pulmonary arterial hypertension, asthma, and atopic dermatitis.
Is CytoAgents a public or private company?
CytoAgents is a private company. It is classified as venture growth investor backed and is currently operating.
When was CytoAgents founded?
CytoAgents was founded in 2018. It employs 1 to 10 people.
Where is CytoAgents based?
CytoAgents is headquartered in Pittsburgh, United States, in the North America region.
How does CytoAgents make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are CytoAgents's main competitors?
Direct peers on record are Kiniksa Pharmaceuticals, Incyte Corporation and United Therapeutics. Broad incumbents are Roche (Genentech), Regeneron / Sanofi (Dupixent), AbbVie (Rinvoq) and Acceleron Pharma (Merck). Emerging players are Cartesian Therapeutics, AnaptysBio and Aldeyra Therapeutics.
Does CytoAgents have an API?
No public API is recorded for CytoAgents.
What industry is CytoAgents in?
CytoAgents's product category is Immunomodulatory Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 3254 and its SIC code is 2834.